New eczema drug candidate enters first human safety tests
NCT ID NCT06920693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety of a new drug called GB-7624 in 40 healthy adults. It is the first time this drug is being given to humans. The study gives single or multiple doses under the skin to see if it is safe and how the body processes it. If successful, it may eventually be developed as a treatment for atopic dermatitis (eczema).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GB-7624
- What this could lead to
- If safe, this could lead to a new treatment option for atopic dermatitis (eczema) that helps control the condition.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only tests safety and dosing, not whether it works for eczema. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Generate Biomedicines Clinical Site
Herston, Queensland, 4007, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ozonated oil soothe eczema in kids?
- Can a Skin-Repairing cream soothe eczema?
- Can a new antibody calm severe eczema?
- Microscopic skin scans may reveal how a new eczema drug reshapes the skin
- Menthol gloves may offer quick itch relief for eczema sufferers
- One pill may tame both itchy skin and stubborn liver disease